Daratumumab

Daratumumab
	Fab fragment of daratumumab (teal/green) binding CD38 (pale pink). From PDB entry 7DHA
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD38
Clinical data
Trade names	Darzalex, Darzalex SC
AHFS/Drugs.com	Monograph
MedlinePlus	a616002
License data	US DailyMed: Daratumumab;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous, subcutaneous
ATC code	L01FC01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	945721-28-8 ;
DrugBank	DB09331 ;
ChemSpider	none;
UNII	4Z63YK6E0E;
KEGG	D10777 ;
ChEMBL	ChEMBL1743007;
Chemical and physical data
Formula	C6466H9996N1724O2010S42
Molar mass	145391.67 g·mol−1
	(what is this?) (verify)

Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.

Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma. It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

It is available in combination with hyaluronidase as daratumumab/hyaluronidase (brand name Darzalex Faspro).